Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

被引：0

作者：

Brown, Jennifer R. ^{[1
]}

Eichhorst, Barbara ^{[2
]}

Ghia, Paolo ^{[3
,4
]}

Kater, A. P. ^{[5
]}

Li, Jianyong ^{[6
]}

Khurana, Sudha ^{[7
]}

Elhamy, Mostafa ^{[7
]}

Wang, Min Hui ^{[7
]}

Seymour, John F. ^{[8
,9
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Hosp Cologne, Cologne, Germany

[3] Univ Vita Salute Raffaele, Milan, Italy

[4] IRCCS Osped San Raffaele, Milan, Italy

[5] Amsterdam UMC, Amsterdam, Netherlands

[6] Nanjing Med Univ, Affiliated Hosp 1, Jiansu Sheng, Peoples R China

[7] Acerta Pharma, San Francisco, CA USA

[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[9] Royal Melbourne Hosp, Melbourne, Vic, Australia

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷

关键词：

CLL; chronic lymphocytic leukemia; acalabrutinib; Bruton tyrosine kinase inhibitor; combination therapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CLL-092

引用

页码：S221 / S222

页数：2

共 50 条

[21] Acalabrutinib with Obinutuzumab in Treatment-Naive (TN) and Relapsed/Refractory (R/R) Patients with Chronic Lymphocytic Leukemia (CLL): 3-Year Follow-Up
Woyach, Jennifer A.
Rogers, Kerry A.
Bhat, Seema
Blachly, James
Jianfar, Mojgan
Frigault, Melanie M.
Hamdy, Ahmed
Izumi, Raquel
Munugalavadla, Veerendra
Quah, Cheng
Wang, Min Hui
Byrd, John C.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S281 - S281
[22] Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study
Takizawa, Jun
Teshima, Takanori
Ennishi, Daisuke
Ichikawa, Satoshi
Suzuki, Ritsuro
Kojima, Akira
Takahashi, Yusuke
Hayashi, Nobuya
Kawasumi, Hisashi
Murayama, Kosho
Cheung, Patricia
Kawata, Toshio
Izutsu, Koji
LEUKEMIA & LYMPHOMA, 2024, 65 (11) : 1586 - 1594
[23] Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia
Rogers, Kerry A.
Huang, Ying
Ruppert, Amy S.
Abruzzo, Lynne V.
Andersen, Barbara L.
Awan, Farrukh T.
Bhat, Seema A.
Dean, Allison
Lucas, Margaret
Banks, Christin
Grantier, Cara
Heerema, Nyla A.
Lozanski, Gerard
Maddocks, Kami J.
Valentine, Thomas R.
Weiss, David M.
Jones, Jeffrey A.
Woyach, Jennifer A.
Byrd, John C.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3626 - +
[24] A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia
Izutsu, Koji
Kinoshita, Tomohiro
Takizawa, Jun
Fukuhara, Suguru
Yamamoto, Go
Ohashi, Yasuo
Suzumiya, Junji
Tobinai, Kensei
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 408 - 415
[25] Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)
Abrisqueta, Pau
Gonzalez-Barca, Eva
Ferra, Christelle
Rios-Herranz, Eduardo
de la Mata, Margarita Fernandez
Delgado, Julio
Andreu, Rafael
Hernandez-Rivas, Jose angel
Terol, Maria Jose
Navarro, Almudena
Vidriales, M. Belen
Baltasar, Patricia
De la Serna, Javier
Ramirez, Angel
Ballester, Carmen
Moreno, Carol
Garcia-Marco, Jose Antonio
Cordoba, Raul
Yanez, Lucrecia
Casado, Luis Felipe
Gonzalez, Marcos
Bosch, Francesc
ECLINICALMEDICINE, 2024, 73
[26] Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study
Leblond, Veronique
Aktan, Melih
Ferra Coll, Christelle M.
Dartigeas, Caroline
Kisro, Jens
Montillo, Marco
Raposo, Joao
Merot, Jean-Louis
Robson, Susan
Gresko, Ekaterina
Bosch, Francesc
Stilgenbauer, Stephan
Foa, Robin
HAEMATOLOGICA, 2018, 103 (11) : 1889 - 1898
[27] Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Previously Untreated Chronic Lymphocytic Leukemia
Shah, Arpita
ANNALS OF PHARMACOTHERAPY, 2014, 48 (10) : 1356 - 1361
[28] 2-CHLORODEOXYADENOSINE (CDA) FOR PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL)
DELANNOY, A
MARTIAT, P
GALA, JL
DENEYS, V
FERRANT, A
BOSLY, A
SCHEIFF, JM
MICHAUX, JL
LEUKEMIA, 1995, 9 (07) : 1130 - 1135
[29] Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Rogers, Kerry A.
Thompson, Philip A.
Allan, John N.
Coleman, Morton
Sharman, Jeff P.
Cheson, Bruce D.
Izumi, Raquel
Frigault, Melanie M.
Quah, Cheng
Raman, Rakesh K.
Wang, Min Hui
Kipps, Thomas J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S282 - S283
[30] Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
Soumerai, Jacob D.
Mato, Anthony R.
Dogan, Ahmet
Seshan, Venkatraman E.
Joffe, Erel
Flaherty, Kelsey
Carter, Jason
Hochberg, Ephraim
Barnes, Jeffrey A.
Hamilton, Audrey M.
Abramson, Jeremy S.
Batlevi, Connie L.
Matasar, Matthew J.
Noy, Ariela
Owens, Colette N.
Palomba, M. Lia
Kumar, Anita
Takvorian, Tak
Ni, Ai
Choma, Morgan
Friedman, Chaya
Chadha, Puja
Simkins, Elizabeth
Ruiters, Jade
Sechio, Sidney
Portman, Daneal
Ramos, Lauren
Nolet, Natascha
Mahajan, Neena
Martignetti, Rosalba
Mi, Joanna
Scorsune, Krista
Lynch, Julia
McGree, Brianne
Hughes, Stephanie
Grieve, Clare
Roeker, Lindsey E.
Thompson, Meghan
Johnson, P. Connor
Roshal, Mikhail
Huang, Jane
Biondo, Juliana
Wu, Qun
Jacob, Allison
Abdel-Wahab, Omar
Zelenetz, Andrew D.
LANCET HAEMATOLOGY, 2021, 8 (12): : E879 - E890

← 1 2 3 4 5 →